Literature DB >> 31142625

Development and validation of a prognostic nomogram for early-onset colon cancer.

Chaoran Yu1,2,3, Yujie Zhang4.   

Abstract

The present study was to develop a prognostic nomogram to predict overall survival (OS) and cancer-specific survival (CSS) in early-onset colon cancer (COCA, age < 50). Patients diagnosed as COCA between 2004 and 2015 were retrieved from the surveillance, epidemiology, and end results (SEER) database. All included patients were assigned into training and validation sets. Univariate and multivariate analysis were used to identify independent prognostic variables for the construction of nomogram. The discrimination and calibration plots were used to measure the accuracy of the nomogram. A total of 11220 patients were included from the SEER database. The nomograms were established based on the variables significantly associated with OS and CSS using cox regression models. Calibration plots indicated that both nomograms in OS and CSS exhibited high correlation to actual observed results. The nomograms also displayed improved discrimination power than tumor-node-metastasis (TNM) stage and SEER stage both in the training and validation sets. The monograms established in the present study provided an alternative tool to both OS and CSS prognostic prediction compared with TNM and SEER stages.
© 2019 The Author(s).

Entities:  

Keywords:  Cancer-specific survival; Colon cancer; Nomogram; Overall survival

Year:  2019        PMID: 31142625      PMCID: PMC6617053          DOI: 10.1042/BSR20181781

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


Introduction

Colorectal cancer (CRC) is one of the common malignant death-caused diseases worldwide [1]. In the United States, CRC patients were newly registered in approximately 130000 cases with over 50000 death reports [1]. In Europe, CRC is both the second common cause of death in the European Union with 215000 cases and second common cancer sites with 447000 cases [2]. In Singapore, CRC ranks top in incidence and second in cause of cancer death [3]. Meanwhile, the incidence and death rates of CRC have been increasing in China [4]. Although the incidence and death rates have been reduced in CRC patients older than 50, the incidence of early-onset CRC (age < 50) increases by 22% and the death rate increases by 13% in the United States during the last decade [1]. Radical surgical intervention remains the primary treatment for CRC [5]. Nevertheless, approximately 25% of CRC patients develop recurrence or distant metastasis [6]. Intriguingly, combinational therapies of chemotherapy and targeted drugs have significantly improved the therapeutic benefits in CRC [7,8]. However, the intrinsic complexity of early-onset CRC remains largely unknown. Generally, early-onset tumors are more likely to be associated with germline genotypes. Hong et al. discovered seven genes (CYR61, UCHL1, FOS, FOSB, EGR1, VIP, and KRT24) as a susceptibility gene set associated with early-onset CRC patients [9]. Ågesen et al. indicated that CLC and IFNAR1 were differentially expressed between young and elderly CRC patients with respect to somatic gene expression, highlighting the genomic complexity associated with age [10]. Nevertheless, the overall prognosis of early-onset CRC remains largely constrained by clinical heterogeneity. Therefore, a refined nomogram system is needed to contribute to the prognosis evaluation of early-onset CRC. In fact, given the genomic-features and clinic-management variances between the colon cancer (COCA) and rectal cancer [11,12], the present study exclusively focused on COCA. Previously, the tumor-node-metastasis (TNM) cancer staging system of American Joint Committee on Cancer (AJCC) has been periodically updated for effective cancer management [13]. However, increasing studies indicated that other factors, including age, race, and tumor site have also been in association with tumor prognosis in individual case [10,14,15]. Therefore, it is needed to establish a prognostic indicator system specified for early-onset COCA patients. The nomogram-based statistical method has been widely implemented in prognosis-associated clinical studies with comparable results [16,17]. In fact, nomograms enable specifically individual survival scores by dynamically incorporating clinical variables with technical feasibility and reproducibility. However, nomograms for the prognosis of early-onset COCA have not been fully characterized. Because of this need, a prognostic nomogram based on the large population of COCA data retrieved from the surveillance, epidemiology, and end results (SEER) program (2004–2015) was developed to predict individualized survival in early-onset COCA.

Materials and methods

Patients

The clinicopathological data of all COCA patients were retrieved from the SEER program of the United States National Cancer Institute (NCI). SEER program is established to comprehensively collect clinical information on various cancer types for associated incidence, prevalence, and prognostic studies [18,19]. Patients diagnosed with COCA from 2004 to 2015 were retrieved. The histological code [International Classification of Diseases for Oncology, Third edition (ICD-O-3)] and the cancer staging scheme (version 0204) were used to identify all the patients. The inclusion criteria were (1) tumor site was colon excluding rectum; (2) diagnosis had been microscopically confirmed; (3) age <50; (4) complete TNM stage information; (5) COCA was the first and the only cancer primary; (6) surgery had been performed. All the included patients were randomly assigned to a training set and validation set. The present study was performed with the data from SEER program and reference number 14622-Nov2017. No informed consent or institutional review board approval was required in the present study due to the public-available data of SEER.

Variables

Clinical variables of COCA patients were extracted, including age, sex, marital status, histological grade, tumor site, TNM stage, tumor size, SEER stage follow-up information, and corresponding death causes. Overall survival (OS) was the primary endpoint, defined as the time period from the diagnosis to the death or last follow-up. Cancer-specific survival (CSS) was the second endpoint, defined as the time period from the diagnosis to the death caused by COCA or censoring. Age and tumor size were transformed into categorical variables.

Construction of the nomogram

All the categorical variables were presented with frequencies and proportions, and analyzed by a chi-square test. The Kaplan–Meier method and log-rank test were used to analyze each potential prognostic variable. All significant variables from univariate analysis were subject to a multivariate Cox proportional hazards analysis. The construction of nomogram was based on the multivariate cox regression model by the R statistical package rms (R Foundation for Statistical Computing, Vienna, Austria).

Validation of the nomogram

The validation set was used for the validation of the nomogram by the discrimination, calibration, and bootstrap resampling. The concordance index (C-index) was used to measure the difference between the observed and predicted results from the constructed nomogram. Receiver operating characteristics curve (ROC) analysis was performed for sensitivity and specificity. We further compared the nomogram, the TNM stage, and the SEER stage using the C-index. Calibration plot was used to visualize the variance between nomogram-predicted prognosis and actual prognosis. The 45-degree line in a calibration plot was used as a perfect model to compare the actual outcomes. Furthermore, decision curve analysis (DCA) was used to depict the threshold probabilities ranges in comparison with TNM stage and SEER stage. All the statistical analyses were performed using R software version 3.3.0 (Vienna, Austria; www.r-project.org). P-value <0.05 was considered as statistically significant.

Results

Patient characteristics

A total of 11220 eligible cases were included in the present study with 7856 cases randomly assigned to the training set and 3364 into the validation set (Figure 1). 52.2% of all patients were married and 41.7% were unmarried (also including widowed, single, and divorced). For all the early-onset patients, 7780 were between 40 and 50 years old (69.3%), whereas 2383 were between 30 and 40 years old (21.2%). 1057 were younger than 30 years old (9.4%). The majority of race was white (73.1%). The most common tumor site for COCA in the present study was the sigmoid colon (35.3%), followed by appendix (14.7%) and cecum (13.8%) and ascending colon (12.4%). For tumor size, 2–5 cm was the most common type (38.7%), followed by 5–10 cm (30.7%). 52.5% of all the patients were N0 whereas 80.1% were M0 in AJCC stage system. 42.5% of all the patients were regional in SEER stage (Table 1).
Figure 1

Flow diagram of the included colon cancer patients

Table 1

The demographics and pathological characteristics of included patients

VariablesAll patientsTraining setValidation setP-value
n (%)n (%)n (%)
Total11220 (100)7856 (70)3364 (30)
Marital status0.236
  Married5862 (52.2)4064 (51.7)1798 (53.4)
  Unmarried4679 (41.7)3315 (42.2)1364 (40.5)
  Unknown679 (6.1)477 (6.1)202 (6.0)
Sex0.172
  Male5552 (49.5)3921 (49.9)1631 (48.5)
  Female5668 (50.5)3935 (50.1)1733 (51.5)
Age0.307
  <301057 (9.4)751 (9.6)306 (9.1)
  30–402383 (21.2)1692 (21.5)691 (20.5)
  >407780 (69.3)5413 (68.9)2367 (70.4)
Race0.021
  White8206 (73.1)5700 (72.6)2506 (74.5)
  Black1776 (15.8)1297 (16.5)479 (14.2)
  Other1101 (9.8)768 (9.8)333 (9.9)
  Unknown137 (1.2)91 (1.2)46 (1.4)
Grade0.505
  I1595 (14.2)1111 (14.1)484 (14.4)
  II6658 (59.3)4654 (59.2)2004 (59.6)
  III1720 (15.3)1233 (15.7)487 (14.5)
  IV419 (3.7)287 (3.7)132 (3.9)
  Unknown828 (7.4)571 (7.3)257 (7.6)
Site0.553
  Appendix1645 (14.7)1161 (14.8)484 (14.4)
  Ascending colon1390 (12.4)950 (12.1)440 (13.1)
  Cecum1552 (13.8)1115 (14.2)437 (13.0)
  Descending colon925 (8.2)651 (8.3)274 (8.1)
  Hepatic flexure364 (3.2)247 (3.1)117 (3.5)
  Large intestine, NOS199 (1.8)133 (1.7)66 (2.0)
  Sigmoid colon3959 (35.3)2772 (35.3)1187 (35.3)
  Splenic flexure359 (3.2)255 (3.2)104 (3.1)
  Transverse colon827 (7.4)572 (7.3)255 (7.6)
AJCC stage0.96
  I2761 (24.6)1926 (24.5)835 (24.8)
  II2681 (23.9)1877 (23.9)804 (23.9)
  III3547 (31.6)2495 (31.8)1052 (31.3)
  IV2231 (19.9)1558 (19.8)673 (20.0)
AJCC T0.725
  T12346 (20.9)1644 (20.9)702 (20.9)
  T21016 (9.1)696 (8.9)320 (9.5)
  T35313 (47.4)3724 (47.4)1589 (47.2)
  T42545 (22.7)1792 (22.8)753 (22.4)
AJCC N0.548
  N05891 (52.5)4117 (52.4)1774 (52.7)
  N13001 (26.7)2123 (27.0)878 (26.1)
  N22328 (20.7)1616 (20.6)712 (21.2)
AJCC M0.853
  M08989 (80.1)6298 (80.2)2691 (80.0)
  M12231 (19.9)1558 (19.8)673 (20.0)
Tumor size
  ≤2cm1912 (17.0)1337 (17.0)575 (17.1)0.249
  >2 to ≤5 cm4343 (38.7)3023 (38.5)1320 (39.2)
  >5 to ≤10 cm3447 (30.7)2452 (31.2)995 (29.6)
  >10 cm534 (4.8)360 (4.6)174 (5.2)
  NA984 (8.8)684 (8.7)300 (8.9)
SEER stage0.439
  Localized4054 (36.1)2809 (35.8)1245 (37.0)
  Regional4764 (42.5)3359 (42.8)1405 (41.8)
  Distant2402 (21.4)1688 (21.5)714 (21.2)

Establishment of the nomogram

Marital status, age, race, grade, site, TNM stage, tumor size, and SEER stage were significantly associated with OS by univariate analysis in the training set (Table 2). Further multivariate analysis indicated that marital status, race, grade, TNM stage, tumor size, and SEER stage were significantly associated with OS. Therefore, a nomogram of 3- and 5-year OS was established with the independent variables (Figure 2A). In addition, the prognostic values and clinicopathological characterization of patients with different marital status were displayed (Supplementary Figure S1 and Table S1). Moreover, each variable was also examined for CSS and therefore used to build a CSS nomogram as well (Table 3 and Figure 2B).
Table 2

Univariate and multivariate analyses of overall survival (OS) in the training set of early-onset colon cancer patients

VariablesUnivariate analysisMultivariate analysis
P-valueHR(95%CI)P-value
Marital status<0.001
  MarriedReference
  Unmarried1.45(1.28–1.64)<0.001
  Unknown1.39(1.06–1.82)0.017
Sex0.215
  Male
  Female
Age0.027
  <30Reference
  30–400.96(0.73–1.26)0.769
  >401.10(0.86–1.41)0.452
Race<0.001
  WhiteReference
  Black1.20(1.04–1.39)0.015
  Other0.91(0.74–1.12)0.371
  Unknown9.03e−07(0–Inf)0.982
Grade<0.001
  IReference
  II1.22(0.91–1.65)0.187
  III2.02(1.49−2.75)<0.001
  IV2.22(1.56–3.16)<0.001
  Unknown1.66(1.10–2.51)0.016
Site<0.001
  AppendixReference
  Ascending colon1.23(0.89–1.70)0.214
  Cecum1.16(0.85–1.59)0.348
  Descending colon0.98(0.70–1.40)0.930
  Hepatic flexure1.12(0.73–1.71)0.603
  Large intestine, NOS1.31(0.82–2.10)0.256
  Sigmoid colon0.89(0.66–1.21)0.467
  Splenic flexure1.10(0.74–1.63)0.639
  Transverse colon1.07(0.75–1.51)0.716
AJCC stage<0.001
  I
  II
  III
  IV
AJCC T<0.001
  T1Reference
  T22.77(1.37–5.63)0.005
  T34.21(2.19–8.10)<0.001
  T45.54(2.86–10.72)<0.001
AJCC N<0.001
  N0Reference
  N11.73(1.41–2.11)<0.001
  N22.34(1.91–2.86)<0.001
AJCC M<0.001
  M0Reference
  M12.89(1.93–4.31)<0.001
Tumor size<0.001
  ≤2cmReference
  >2 to ≤5 cm1.15(0.83–1.60)0.389
  >5 to ≤10 cm1.16(0.84–1.62)0.368
  >10 cm1.48(1.00–2.20)0.0497
SEER stage<0.001
  LocalizedReference
  Regional1.61(1.13–2.28)0.008
  Distant3.03(1.80–5.12)<0.001
Figure 2

Nomograms for early-onset colon cancer patients

(A) Nomograms for 3- and 5-year-associated OS. (B) Nomograms for 3- and 5-year-associated CSS.

Table 3

Univariate and multivariate analyses of Cancer-specific survival (CSS) in the training set of early-onset colon cancer patients

VariablesUnivariate analysisMultivariate analysis
P-valueHR(95%CI)P-value
Marital status<0.001
  MarriedReference
  Unmarried1.40(1.23–1.60)<0.001
  Unknown1.34(1.01–1.78)0.041
Sex0.352
  Male
  Female
Age0.054
  <30Reference
  30–400.97(0.73–1.29)0.829
  >401.09(0.84–1.41)0.508
Race<0.001
  WhiteReference
  Black1.19(1.02–1.39)0.028
  Other0.95(0.78–1.17)0.652
  Unknown0.90(0–Inf)0.984
Grade<0.001
  IReference
  II1.32(0.96–1.82)0.092
  III2.27(1.64–3.16)<0.001
  IV2.33(1.60–3.41)<0.001
  Unknown1.79(1.15–2.78)0.010
Site<0.001
  AppendixReference
  Ascending colon1.09(0.78–1.52)0.613
  Cecum1.01(0.73–1.39)0.953
  Descending colon0.85(0.59–1.21)0.367
  Hepatic flexure1.05(0.68–1.61)0.830
  Large intestine, NOS1.20(0.75–1.94)0.450
  Sigmoid colon0.80(0.59–1.09)0.156
  Splenic flexure0.94(0.63–1.42)0.778
  Transverse colon0.94(0.66–1.34)0.730
AJCC stage<0.001
  I
  II
  III
  IV
AJCC T<0.001
  T1Reference
  T24.12(1.66–10.18)0.002
  T36.50(2.77–15.24)<0.001
  T48.59(3.64–20.23)<0.001
AJCC N<0.001
  N0Reference
  N11.88(1.52–2.32)<0.001
  N22.55(2.06–3.16)<0.001
AJCC M<0.001
  M0Reference
  M13.35(2.17–5.17)<0.001
Tumor size<0.001
  ≤2cmReference
  >2 to ≤5 cm1.11(0.79–1.55)0.565
  >5 to ≤10 cm1.13(0.80–1.59)0.484
  >10 cm1.51(1.01–2.27)0.046
SEER stage<0.001
  LocalizedReference
  Regional1.79(1.20–2.66)0.004
  Distant3.16(1.77–5.66)<0.001

Nomograms for early-onset colon cancer patients

(A) Nomograms for 3- and 5-year-associated OS. (B) Nomograms for 3- and 5-year-associated CSS.

Nomogram validation

The nomograms were both internally and externally validated. The internal validation was performed via the training cohort with the C-index as 0.835 (95%CI, 0.823–0.847) in OS and 0.851 (95%CI, 0.840–0.862) in CSS, respectively (Table 4). The external validation was performed via the validation cohort with the C-index as 0.848 (95%CI, 0.831–0.865) in OS and 0.863 (95%CI, 0.847–0.879) in CSS, respectively. Calibration plots of the validations of OS and CSS nomograms indicated highly correlations between the predicted and observed results (Figures 3 and 4).
Table 4

Comparison of C-indexes between the nomograms, TNM, and SEER stages in early-onset colon cancer patients

Training setValidation set
HR95%CIP-valueHR95%CIP-value
OSNomogram0.8350.823–0.8470.8480.831–0.865
SEER stage0.7800.767–0.793<0.0010.7980.780–0.816<0.001
TNM 7th stage0.8180.806–0.8300.0270.840.823–0.8570.126
CSSNomogram0.8510.840–0.8620.8630.847–0.879
SEER stage0.7950.783–0.807<0.0010.8130.795–0.831<0.001
TNM 7th stage0.8350.823–0.8470.0340.8580.842–0.8740.189
Figure 3

Calibration plots of the training and validation sets for the OS-associated nomograms

(A,B) The calibration plots of the training set in 3- and 5-year OS. (C,D) The calibration plots of the validation set in 3- and 5-year OS.

Figure 4

Calibration plots of the training and validation sets for the CSS-associated nomograms

(A,B) The calibration plots of the training set in 3- and 5-year CSS. (C,D) The calibration plots of the validation set in 3- and 5-year CSS.

Calibration plots of the training and validation sets for the OS-associated nomograms

(A,B) The calibration plots of the training set in 3- and 5-year OS. (C,D) The calibration plots of the validation set in 3- and 5-year OS.

Calibration plots of the training and validation sets for the CSS-associated nomograms

(A,B) The calibration plots of the training set in 3- and 5-year CSS. (C,D) The calibration plots of the validation set in 3- and 5-year CSS. The area under ROC curve (AUC) was analyzed for both the training and validation set, respectively (Figure 5A–H). Furthermore, the comparisons between the nomograms and TNM stage and SEER stage were performed. The OS and CSS nomograms showed comparable results to TNM stage and SEER stage in both training and validation sets (Table 4). Moreover, the DCA results of nomograms also strengthened the clinical applicability of nomograms from OS and CSS with superiority over TNM stage and SEER stage (Figure 6).
Figure 5

ROC analysis for training and validation sets

(A) The ROC of 3 years OS for training set; (B) the ROC of 5 years OS for training set; (C) the ROC of 3 years OS for validation set; (D) the ROC of 5 years OS for validation set; (E) the ROC of 3 years CSS for training set; (F) the ROC of 5 years CSS for training set; (G) the ROC of 3 years CSS for validation set; and (H) the ROC of 5 years CSS for validation set.

Figure 6

DCA of the training and validation sets for the CSS- and OS-associated nomograms

(A,B) The DCA of nomogram in training set for OS (A) and CSS (B). (C,D) The DCA of nomogram in validation set for OS (C) and CSS (D).

ROC analysis for training and validation sets

(A) The ROC of 3 years OS for training set; (B) the ROC of 5 years OS for training set; (C) the ROC of 3 years OS for validation set; (D) the ROC of 5 years OS for validation set; (E) the ROC of 3 years CSS for training set; (F) the ROC of 5 years CSS for training set; (G) the ROC of 3 years CSS for validation set; and (H) the ROC of 5 years CSS for validation set.

DCA of the training and validation sets for the CSS- and OS-associated nomograms

(A,B) The DCA of nomogram in training set for OS (A) and CSS (B). (C,D) The DCA of nomogram in validation set for OS (C) and CSS (D).

Discussion

The present study established OS and CSS prognostic nomograms for COCA patients derived from the SEER program with favorable discrimination and calibration and comparable predictive capability. In fact, the nomogram highlighted the clinical significance of marital status, race, grade, TNM stage, tumor size, and SEER stage in early-onset COCA patients. The role of marital status in cancer had been previously investigated in SEER program [20]. Married patients were featured by less metastatic diseases, reduced cancer-specific deaths, and more likely to receive definitive therapy [20]. For colon cancer, married patients were more likely to be diagnosed at earlier stage and to receive surgical treatment [21]. Moreover, married patients had significantly lower risk in CSS [21]. Our study also indicated the consistent results. Noteworthy, race, sex, and tumor site were not an independent prognostic variable for early-onset COCA patients in the present study. In fact, race and sex has been viewed as one of the essence variables for cancer treatment [22-24]. Tumor site in CRC had been intensively studied with large population [25,26]. Right-sided colon cancers exhibited increased mortality risk compared with left-sided colon cancers. However, no specific tumor site has been under investigation. Intriguingly, although age was associated with significant prognosis in univariate analysis, it remained insignificant in multivariate analysis, indicating that the subtle stratification between age <30, 30–40, and 40–50 required further investigation. Of note, tumor size was an independent prognostic variable in the nomogram in the present study. In fact, only the tumor >10 cm exhibited significant higher prognostic risk than tumor <2cm whereas the rest stratification remained insignificant. It was possible that the tumor size could be one of the insightful variables for the prognostic risk prediction. Up to now, nomogram statistical tool provided reasonable, reproducible, and rigid algorithms for individualized prognostic assessment. It has been implemented as prognostic indicators for several cancer types including pancreas, gastrointestinal stromal tumor (GIST), and gastric cancer [16,27,28]. In pancreatic cancer, a nomogram constructed by CSS data of 53028 patients diagnosed as pancreatic cancer from the SEER program and eight independent clinical variables (C-index = 0.734) [16]. For a total of 5622 GIST patients, similar nomograms were also established by seven independent clinical variables in both CSS and OS data. Noteworthy, these nomogram exhibited better discrimination power than TNM stage and SEER stage systems [27]. Furthermore, Liu et al. identified a prognostic nomogram for disease specific survival (DSS) of gastric cancer patients using the SEER program and external validation set [28]. Collectively, incorporation of numerous prognostic-associated clinical variables into nomogram algorithms could display comparable staging system and more disease-specific features. The limitations of the present study were the lack of external clinical data from independent sources and the vacant data on chemotherapy and radiotherapy, as well as the genomic phenotypes in SEER program. Moreover, given the potential confounding factors within the surgical patterns, surgical styles, postoperative complications, and some surgical items remaining contradictory, the COCA patients without surgery or the complete TNM stage data were excluded from the present study.

Conclusion

The nomograms established in the present study provided an alternative tool to both OS and CSS prognostic prediction compared with TNM and SEER stages.

Availability of data and materials

The datasets supporting the conclusion of this article are included within the article.

Human participants and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.
Supplementary Table S1

Clinicopathological characterization of early-onset colon cancer patients stratified by marital status.

  27 in total

Review 1.  The surveillance, epidemiology, and end results program: a national resource.

Authors:  B F Hankey; L A Ries; B K Edwards
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-12       Impact factor: 4.254

Review 2.  Racial and ethnic disparities in the receipt of cancer treatment.

Authors:  Vickie L Shavers; Martin L Brown
Journal:  J Natl Cancer Inst       Date:  2002-03-06       Impact factor: 13.506

3.  Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program.

Authors:  Matthew J Hayat; Nadia Howlader; Marsha E Reichman; Brenda K Edwards
Journal:  Oncologist       Date:  2007-01

4.  The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

Authors:  Stephen B Edge; Carolyn C Compton
Journal:  Ann Surg Oncol       Date:  2010-06       Impact factor: 5.344

Review 5.  Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.

Authors:  Eric Van Cutsem; Bernard Nordlinger; Rene Adam; Claus-Henning Köhne; Carmelo Pozzo; Graeme Poston; Marc Ychou; Philippe Rougier
Journal:  Eur J Cancer       Date:  2006-08-10       Impact factor: 9.162

6.  Marital status and colon cancer outcomes in US Surveillance, Epidemiology and End Results registries: does marriage affect cancer survival by gender and stage?

Authors:  Li Wang; Sven E Wilson; David B Stewart; Christopher S Hollenbeak
Journal:  Cancer Epidemiol       Date:  2011-04-05       Impact factor: 2.984

7.  A susceptibility gene set for early onset colorectal cancer that integrates diverse signaling pathways: implication for tumorigenesis.

Authors:  Yi Hong; Kok Sun Ho; Kong Weng Eu; Peh Yean Cheah
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

8.  Is there a difference in survival between right- versus left-sided colon cancers?

Authors:  Robert A Meguid; Mark B Slidell; Christopher L Wolfgang; David C Chang; Nita Ahuja
Journal:  Ann Surg Oncol       Date:  2008-07-12       Impact factor: 5.344

9.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Authors:  David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

10.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

View more
  7 in total

1.  Genome-Wide Identification of a Novel Autophagy-Related Signature for Colorectal Cancer.

Authors:  Zhi Huang; Jie Liu; Liang Luo; Pan Sheng; Biao Wang; Jun Zhang; Sha-Sha Peng
Journal:  Dose Response       Date:  2019-12-11       Impact factor: 2.658

2.  Application of an Autophagy-Related Gene Prognostic Risk Model Based on TCGA Database in Cervical Cancer.

Authors:  Huadi Shi; Fulan Zhong; Xiaoqiong Yi; Zhenyi Shi; Feiyan Ou; Zumin Xu; Yufang Zuo
Journal:  Front Genet       Date:  2021-02-09       Impact factor: 4.599

3.  NDC1 is a Prognostic Biomarker and Associated with Immune Infiltrates in Colon Cancer.

Authors:  Meng Liu; Rui Yuan; Shifei Liu; Yonggan Xue; Xuning Wang
Journal:  Int J Gen Med       Date:  2021-11-25

4.  Identification of prognostic biomarkers and drug target prediction for colon cancer according to a competitive endogenous RNA network.

Authors:  Daojun Hu; Boke Zhang; Miao Yu; Wenjie Shi; Li Zhang
Journal:  Mol Med Rep       Date:  2020-05-22       Impact factor: 2.952

5.  Development of a Novel Six-miRNA-Based Model to Predict Overall Survival Among Colon Adenocarcinoma Patients.

Authors:  Zhenxiang Rong; Yi Rong; Yingru Li; Lei Zhang; Jingwen Peng; Baojia Zou; Nan Zhou; Zihao Pan
Journal:  Front Oncol       Date:  2020-02-21       Impact factor: 6.244

6.  Development and validation of a nomogram to predict the overall survival of patients with neuroblastoma.

Authors:  Qinglin Liu; Lei Feng; Hao Xue; Wandong Su; Gang Li
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.889

7.  Establishment of prognostic nomogram for elderly colorectal cancer patients: a SEER database analysis.

Authors:  Chaoran Yu; Yujie Zhang
Journal:  BMC Gastroenterol       Date:  2020-10-20       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.